Friday, Nov 20, 2026 The claims desk. Receipts included. POWERED BY LENZ ↗
IsThis

Once-weekly 5 mg tirzepatide produced −15.0% mean weight change at week 72.

The Claim

At week 72 of the Phase 3 SURMOUNT-1 trial, the mean percentage change in body weight was -20.9% with once-weekly 5 mg tirzepatide.

The Short Version

The claim assigns the 15 mg dose’s weight-loss result to the 5 mg dose. At week 72 of the Phase 3 SURMOUNT-1 trial, mean body-weight change was −15.0% with once-weekly 5 mg tirzepatide; −20.9% was the result for 15 mg. The peer-reviewed trial report and FDA records, including the January 2026 label, consistently document this distinction.

Caveats

  • The reported percentages are group means, not guaranteed outcomes for individual patients.
  • The trial publication and FDA records describe the same underlying trial, not independent clinical replications.

The Receipts

  1. Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine

    nejm.org

  2. Revised: 01/2026

    accessdata.fda.gov

  3. Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial

    doi.org

  4. 217806Orig1s000

    accessdata.fda.gov

  5. Tirzepatide Once Weekly for the Treatment of... : New England Journal of Medicine

    ovid.com

  6. Tirzepatide Once Weekly for the Treatment of Obesity - PubMed

    pubmed.ncbi.nlm.nih.gov

  7. Tirzepatide Once Weekly for the Treatment of Obesity - American College of Cardiology

    acc.org

  8. Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their Body Weight Over 72 Weeks | AFP

    aafp.org

  9. Tirzepatide Reduced Significantly the Body Weight in Obese Patients

    doi.org

  10. Tirzepatide: A New Anti-Obesity Medication

    doi.org

+ 19 more sources — see the full list on Lenz

Filed Under

SURMOUNT-1Tirzepatide

More Fact Checks